Personen

TOP 5 Publikationen:

1. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer-Butz A, Mann K, Solbach C, Reischl G, Schwärzler F, Gründer G, Machulla HJ, Bares R, Heinz A. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol Psychiatry. 2008 13(6):606-13, 557.
2. Quednow BB, Brinkmeyer J, Mobascher A, Nothnagel M, Musso F, Gründer G, Savary N, Petrovsky N, Frommann I, Lennertz L, Spreckelmeyer KN, Wienker TF, Dahmen N, Thuerauf N, Clepce M, Kiefer F, Majic T, Mössner R, Maier W, Gallinat J, Díaz-Lacava A, Toliat MR, Thiele H, Nürnberg P, Wagner M, Winterer G. Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci U S A. 2012 109(16):6271-6. Epub 2012 Mar 26.
3. Hansson AC, Gründer G, Hirth N, Noori HR, Spanagel R, Sommer WH. Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neurosci Biobehav Rev. 2018 Sep 19. [Epub ahead of print].
4. Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull. 2019 45(2):350-359. Epub 2018 May 1.
5. Wagner M, Schulze-Rauschenbach S, Petrovsky N, Brinkmeyer J, von der Goltz C, Gründer G, Spreckelmeyer KN, Wienker T, Díaz-Lacava A, Mobascher A, Dahmen N, Clepce M, Thuerauf N, Kiefer F, de Millas JW, Gallinat J, Winterer G. Neurocognitive impairments in non-deprived smokers-results from a population-based multi-center study on smoking-related behavior. Addict Biol. 2013 18(4):752-61. Epub 2012 Feb 17.